These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 39301135)

  • 41. Delamanid and bedaquiline resistance patterns in
    Akbari Aghababa A; Nasiri MJ; Pakzad P; Mirsamadi ES
    New Microbes New Infect; 2024; 60-61():101437. PubMed ID: 38873345
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Analysis of the side effect of QTc interval prolongation in the bedaquiline regimen in drug resistant tuberculosis patients.
    Ardhianto D; Suharjono ; Soedarsono ; Fatmawati U
    J Basic Clin Physiol Pharmacol; 2021 Jun; 32(4):421-427. PubMed ID: 34214323
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Pretomanid with bedaquiline and linezolid for drug-resistant TB: a comparison of prospective cohorts.
    Oelofse S; Esmail A; Diacon AH; Conradie F; Olayanju O; Ngubane N; Howell P; Everitt D; Crook AM; Mendel CM; Wills GH; Olugbosi M; Del Parigi A; Sun E; Calatroni A; Spigelman M; Dheda K
    Int J Tuberc Lung Dis; 2021 Jun; 25(6):453-460. PubMed ID: 34049607
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Principles of chemotherapy for tuberculosis in national tuberculosis programmes of low- and middle-income countries.
    Chiang CY; Lin CJ
    Indian J Tuberc; 2020 Dec; 67(4S):S16-S22. PubMed ID: 33308663
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Molecular determinants of multidrug-resistant tuberculosis in Sierra Leone.
    Blankson HNA; Kamara RF; Barilar I; Andres S; Conteh OS; Dallenga T; Foray L; Maurer F; Kranzer K; Utpatel C; Niemann S
    Microbiol Spectr; 2024 Mar; 12(3):e0240523. PubMed ID: 38289066
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Successful implementation of bedaquiline for multidrug-resistant TB treatment in remote Papua New Guinea.
    Taune M; Ustero P; Hiashiri S; Huang K; Aia P; Morris L; Main S; Chan G; du Cros P; Majumdar SS
    Public Health Action; 2019 Sep; 9(Suppl 1):S73-S79. PubMed ID: 31579654
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Implementing novel regimens for drug-resistant TB in South Africa: what can the world learn?
    Ndjeka N; Hughes J; Reuter A; Conradie F; Enwerem M; Ferreira H; Ismail N; Kock Y; Master I; Meintjes G; Padanilam X; Romero R; Schaaf HS; Riele JT; Maartens G
    Int J Tuberc Lung Dis; 2020 Oct; 24(10):1073-1080. PubMed ID: 33126942
    [TBL] [Abstract][Full Text] [Related]  

  • 48. In vitro interaction profiles of the new antitubercular drugs bedaquiline and delamanid with moxifloxacin against clinical Mycobacterium tuberculosis isolates.
    Chandramohan Y; Padmanaban V; Bethunaickan R; Tripathy S; Swaminathan S; Ranganathan UD
    J Glob Antimicrob Resist; 2019 Dec; 19():348-353. PubMed ID: 31226332
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Investigation of bedaquiline resistance and genetic mutations in multi-drug resistant Mycobacterium tuberculosis clinical isolates in Chongqing, China.
    Hu Y; Fan J; Zhu D; Liu W; Li F; Li T; Zheng H
    Ann Clin Microbiol Antimicrob; 2023 Feb; 22(1):19. PubMed ID: 36855179
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Treatment outcomes in patients with drug-resistant TB-HIV co-infection treated with bedaquiline and linezolid.
    Padayatchi N; Bionghi N; Osman F; Naidu N; Ndjeka N; Master I; Brust JCM; Naidoo K; Ramjee A; O Donnell M
    Int J Tuberc Lung Dis; 2020 Oct; 24(10):1024-1031. PubMed ID: 33126934
    [No Abstract]   [Full Text] [Related]  

  • 51. Predicting the Outcomes of New Short-Course Regimens for Multidrug-Resistant Tuberculosis Using Intrahost and Pharmacokinetic-Pharmacodynamic Modeling.
    Doan TN; Cao P; Emeto TI; McCaw JM; McBryde ES
    Antimicrob Agents Chemother; 2018 Dec; 62(12):. PubMed ID: 30249697
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Pretomanid for tuberculosis treatment: an update for clinical purposes.
    Occhineri S; Matucci T; Rindi L; Tiseo G; Falcone M; Riccardi N; Besozzi G
    Curr Res Pharmacol Drug Discov; 2022; 3():100128. PubMed ID: 36105740
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Safety and Effectiveness Outcomes From a 14-Country Cohort of Patients With Multi-Drug Resistant Tuberculosis Treated Concomitantly With Bedaquiline, Delamanid, and Other Second-Line Drugs.
    Huerga H; Khan U; Bastard M; Mitnick CD; Lachenal N; Khan PY; Seung KJ; Melikyan N; Ahmed S; Rich ML; Varaine F; Osso E; Rashitov M; Salahuddin N; Salia G; Sánchez E; Serobyan A; Rafi Siddiqui M; Grium Tefera D; Vetushko D; Yeghiazaryan L; Holtzman D; Islam S; Kumsa A; Jacques Leblanc G; Leonovich O; Mamsa S; Manzur-Ul-Alam M; Myint Z; Padayachee S; Franke MF; Hewison C
    Clin Infect Dis; 2022 Oct; 75(8):1307-1314. PubMed ID: 35243494
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Establishing the Safety and Efficacy of Bedaquiline-Containing Regimen for the Treatment of Drug-Resistant Tuberculosis: A Systematic Review and Meta-Analysis of Randomized Clinical Trials.
    Jihwaprani MC; Sun Y; Rizky WC; Sula I; Saquib N
    Pulm Med; 2024; 2024():5542658. PubMed ID: 39157539
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Coadministration of bedaquiline and pyrifazimine reduce exposure to toxic metabolite N-desmethyl bedaquiline.
    Ding Y; Liu H; Wang F; Fu L; Zhu H; Fu S; Wang N; Zhuang X; Lu Y
    Front Pharmacol; 2023; 14():1154780. PubMed ID: 37860115
    [No Abstract]   [Full Text] [Related]  

  • 56. Baseline and acquired resistance to bedaquiline, linezolid and pretomanid, and impact on treatment outcomes in four tuberculosis clinical trials containing pretomanid.
    Timm J; Bateson A; Solanki P; Paleckyte A; Witney AA; Rofael SAD; Fabiane S; Olugbosi M; McHugh TD; Sun E
    PLOS Glob Public Health; 2023; 3(10):e0002283. PubMed ID: 37851685
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Early treatment outcome of bedaquiline plus optimised background regimen in drug resistant tuberculosis patients.
    Barvaliya SV; Desai MK; Panchal JR; Solanki RN
    Indian J Tuberc; 2020 Apr; 67(2):222-230. PubMed ID: 32553316
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Bedaquiline resistance pattern in clofazimine-resistant clinical isolates of tuberculosis patients.
    Shang Y; Chen S; Shi W; Nie W; Jing W; Huo F; Xue Y; Dong L; Jiang G; Huang H; Chu N
    J Glob Antimicrob Resist; 2023 Jun; 33():294-300. PubMed ID: 37142094
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Comparison of efficacy of bedaquiline and moxifloxacin in drug resistant pulmonary tuberculosis. A prospective observational study.
    Desai G; Purohit G; Borana H; Deokar K; Yogi S
    Monaldi Arch Chest Dis; 2022 May; 93(1):. PubMed ID: 35535455
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Bedaquiline-pretomanid-moxifloxacin-pyrazinamide for drug-sensitive and drug-resistant pulmonary tuberculosis treatment: a phase 2c, open-label, multicentre, partially randomised controlled trial.
    Cevik M; Thompson LC; Upton C; Rolla VC; Malahleha M; Mmbaga B; Ngubane N; Abu Bakar Z; Rassool M; Variava E; Dawson R; Staples S; Lalloo U; Louw C; Conradie F; Eristavi M; Samoilova A; Skornyakov SN; Ntinginya NE; Haraka F; Praygod G; Mayanja-Kizza H; Caoili J; Balanag V; Dalcolmo MP; McHugh T; Hunt R; Solanki P; Bateson A; Crook AM; Fabiane S; Timm J; Sun E; Spigelman M; Sloan DJ; Gillespie SH;
    Lancet Infect Dis; 2024 Sep; 24(9):1003-1014. PubMed ID: 38768617
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.